CVS
A little more CVS in the basket
Assetmark Inc. decided CVS wasn’t quite full enough and increased its stake by 8%, buying 54,111 more shares. After the buy, it held 732,669 shares worth roughly $58.15 million — which is a pretty chunky vote of confidence, even if it arrives in the world’s least dramatic format: institutional paperwork.
Why this matters to you
This isn’t the kind of headline that sends traders scrambling for the popcorn, but it does matter. When a fund keeps leaning into a name like CVS, it can hint that the market’s mood is improving, or at least that some investors think the selloff has gotten a bit too spicy for a boring old healthcare staple.
The bigger CVS backdrop
The article also reminds you that Wall Street is generally wearing rose-colored glasses here:
- Analysts show 20 Buy ratings versus just 3 Hold calls
- The average price target sits around $94.95
- JPMorgan and Sanford C. Bernstein both nudged their views higher recently
And CVS’s last quarterly report wasn’t a disaster either — it beat expectations with adjusted EPS of $1.09 on revenue of $105.69 billion. So between the earnings beat and the steady institutional buying, CVS is starting to look less like a bruised healthcare operator and more like a name that’s slowly getting back into favor.
Big picture: this is more “quiet confidence” than “breakout moment,” but for a stock like CVS, those slow-burn signals can matter a lot more than the loud ones.